OUR LEADERSHIP
Matthew J. D’Onofrio
Matthew J. D’Onofrio is one of our co-founders and currently serves as Evoke’s Chief Executive Officer. He previously served as our President and COO since 2023 and as our Executive Vice President, Chief Business Officer, Secretary, and Treasurer since 2010.
Marilyn R. Carlson, D.M.D., M.D.
Marilyn R. Carlson, D.M.D., M.D. has been the key clinical and regulatory expert for Evoke through the entire development of Gimoti™ (metoclopramide) nasal spray, including all clinical trials conducted in support of the drug. Dr. Carlson joined Evoke at its founding in 2007 as an outside consultant. She joined the company full time in December 2013 as our Chief Medical Officer. Prior to joining Evoke, in 2012 Dr. Carlson helped found Agility Clinical, Inc., a contract research organization focused on supporting virtual companies, start-ups, and companies with orphan drugs. From 2004 to 2012, she served as Vice President, Medical and Regulatory Affairs at Synteract, Inc., a clinical research organization, where she was responsible for safety surveillance, medical monitoring, and regulatory submissions, among other duties. Prior to this, Dr. Carlson served in various leadership roles across a range of pharmaceutical companies as well as holding academic and clinical positions throughout her career. She received a B.A. from Hunter College of the City University of New York, a D.M.D. from the Harvard School of Dental Medicine, and an M.D. from Case Western Reserve University School of Medicine. Dr. Carlson completed an internal medicine residency at The Cleveland Clinic Foundation and holds a certification in regulatory affairs.
Chris Quesenberry
Chris Quesenberry is Chief Commercial Officer for GIMOTI and a Commercial Lead – Integrated Solutions with our commercialization partner EVERSANA. Mr. Quesenberry brings over 30 years of experience in building and executing commercial strategies for pharmaceutical companies and has held roles across the breadth of sales, marketing, and operations. He previously spent 27 years with Merck & Co. and Novo Nordisk, culminating in senior sales and commercial strategy positions, respectively. Recently, Mr. Quesenberry served as the Vice President of Global Commercial Effectiveness at Orexigen Therapeutics and Nalpropion Pharmaceuticals, providing leadership for sales, market access, and sales operations in addition to commercial functions.